You are here: Industry Insights > EC

News List

Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL expresspharma
September 08, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved a variation to the marketing authorisation for IMBRUVICA (ibrutinib) ...
EC signs first Covid-19 vaccine contract with AstraZeneca pharmaceutical-technology
August 28, 2020
The European Commission (EC) has signed its first contract with AstraZeneca for the supply of a Covid-19 vaccine candidate to the European Union (EU) Member States.
EC approves Vertex’s Kaftrio plus ivacaftor for cystic fibrosis patients pharmaceutical-technology
August 25, 2020
Vertex Pharmaceuticals has secured approval from the European Commission (EC) for the use of Kaftrio (ivacaftor / tezacaftor / elexacaftor) in combination with ivacaftor for the treatment of cystic fibrosis (CF).
CureVac concludes talks with EC for Covid-19 vaccine supply pharmaceutical-technology
August 24, 2020
German biopharmaceutical firm CureVac has concluded exploratory discussions with the European Commission (EC) on an advanced purchase agreement (APA) for the company’s mRNA-based Covid-19 vaccine candidate.
AstraZeneca Concludes Agreement with EC for COVID-19 Vaccine americanpharmaceuticalreview
August 19, 2020
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine.
EC and UK sign agreements for Covid-19 vaccines supply pharmaceutical-technology
August 18, 2020
The European Commission (EC) and the UK Government have entered into separate agreements for the supply of potential Covid-19 vaccines.
AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine worldpharmanews
August 17, 2020
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine.
Tinostamustine granted Orphan Drug Designation by European Commission europeanpharmaceuticalreview
August 06, 2020
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis prnasia
August 04, 2020
Pretomanid, a novel compound developed by the non-profit organization TB Alliance, has been granted a conditional marketing authorisation by the European Commission (EC) for treating highly drug-resistant forms of pulmonary tuberculosis (TB).1
EC approves subcutaneous formulation of Remsima® europeanpharmaceuticalreview
July 30, 2020
The European Commission has granted marketing authorisation to Celltrion’s Remsima (infliximab, CT-P13) subcutaneous formulation.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page